{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:23:24Z","timestamp":1770755004938,"version":"3.50.0"},"reference-count":22,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Education, University and Research","award":["PRIN 2020FR7TCL_002"],"award-info":[{"award-number":["PRIN 2020FR7TCL_002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: To report the real-life Brolucizumab therapeutical outcomes of treatment-na\u00efve and non-treatment-na\u00efve eyes with neovascular age-related macular degeneration (nAMD) and to analyze the incidence of therapy-related adverse events. Materials and Methods: A total of 56 eyes of 54 patients diagnosed with nAMD were retrospectively evaluated over a 3-month follow-up. Na\u00efve eyes received a 3-month loading phase, whereas non-na\u00efve eyes were treated with one intravitreal injection + ProReNata scheme. The main outcome measures were best-corrected visual acuity (BCVA) and central retinal thickness (CRT) change. In addition, patients were stratified on the basis of fluid accumulation site, whether intra-retinal (IRF), sub-retinal (SRF), or sub-retinal pigmented epithelium (SRPE), to separately assess the eventual BCVA change in each subgroup. Finally, the incidence of ocular adverse events was evaluated. Results: In na\u00efve eyes, a significant improvement of BCVA (LogMar) was observed at all timepoints from baseline (1 month-Mean Difference (MD): \u22120.13; 2 months MD: \u22120.17; 3 months MD: \u22120.24). In non-na\u00efve eyes, a significant mean change was observed at all timepoints, with the exception of 1-month follow-up (2 months MD: \u22120.08; 3 months MD: \u22120.05). CRT significantly changed in both groups at all timepoints at a similar pace within the first two months, with na\u00efve eyes displaying a larger overall thickness decrease at the end of the follow-up (Group 1 = MD: \u2212123.91 \u00b5m; Group 2 = MD: \u2212110.33 \u00b5m). With respect to the location of the edema, a significant BCVA change was observed in na\u00efve patients with fluid in all three sites at the end of the follow-up (SRPE = MD: \u22120.13 (p = 0.043); SR = MD: \u22120.15 (p = 0.019); IR = MD: \u22120.19 (p = 0.041). Non-na\u00efve patients exhibited significant mean BCVA changes only with respect to SR and IR fluid presence (SRPE = MD: \u22120.13 (p = 0.152); SR = MD: \u22120.15 (p = 0.007); IR = MD: \u22120.06 (p = 0.011). One na\u00efve patient experienced acute-onset anterior and intermediate uveitis which completely resolved after therapy. Conclusions: Brolucizumab was demonstrated to be a safe and efficient alternative in improving both the anatomical and functional parameters of eyes with nAMD in this small, uncontrolled, series of patients.<\/jats:p>","DOI":"10.3390\/medicina59061110","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T01:32:34Z","timestamp":1686274354000},"page":"1110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients"],"prefix":"10.3390","volume":"59","author":[{"given":"Carlo","family":"Gesualdo","sequence":"first","affiliation":[{"name":"Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, Via S. Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Settimio","family":"Rossi","sequence":"additional","affiliation":[{"name":"Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, Via S. Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1688-6646","authenticated-orcid":false,"given":"Clemente Maria","family":"Iodice","sequence":"additional","affiliation":[{"name":"Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, Via S. Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Guarino","sequence":"additional","affiliation":[{"name":"Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, Via S. Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariachiara","family":"Petrella","sequence":"additional","affiliation":[{"name":"Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, Via S. Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana Anna","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, Via S. Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Perrotta","sequence":"additional","affiliation":[{"name":"Eye Unit, G. Rummo Hospital, Via dell\u2019Angelo, 1, 82100 Benevento, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Simonelli","sequence":"additional","affiliation":[{"name":"Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, Via S. Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","article-title":"Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis","volume":"104","author":"Li","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2006.10.040","article-title":"Fifteen-year cumulative incidence of age-related macular degeneration: The Beaver Dam Eye Study","volume":"114","author":"Klein","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in denmark: Year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.clinthera.2021.08.011","article-title":"Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review","volume":"43","author":"Schultz","year":"2021","journal-title":"Clin. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3928\/23258160-20170928-01","article-title":"Treatment Burden in Neovascular AMD: Visual Acuity Outcomes are Associated with Anti-VEGF Injection Frequency","volume":"48","author":"Hussain","year":"2017","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ricci, F., Bandello, F., Navarra, P., Staurenghi, G., Stumpp, M., and Zarbin, M. (2020). Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218242"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","article-title":"Brolucizumab: First Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bilgic, A., Kodjikian, L., Srivastava, S., Dwivedi, S., Banker, A.S., Abukashabah, A., Sudhalkar, A., and Mathis, T. (2021). Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184153"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER","volume":"128","author":"Srivastava","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/bjophthalmol-2020-318672","article-title":"Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study","volume":"106","author":"Bulirsch","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000526851","article-title":"Brolucizumab intravitreal injection in macular neovascularization type 1: VA, SD-OCT and OCTA parameters changes during a 16-weeks follow up","volume":"66","author":"Toto","year":"2023","journal-title":"Ophthalmic Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41433-020-1111-x","article-title":"Brolucizumab-early real-world experience: BREW study","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","article-title":"Early Experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration","volume":"139","author":"Baumal","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/eye.2014.64","article-title":"Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD","volume":"28","author":"Ehlken","year":"2014","journal-title":"Eye"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bilgic, A., Kodjikian, L., de Ribot, F.M., Vasavada, V., Gonzalez-Cortes, J.H., Abukashabah, A., Sudhalkar, A., and Mathis, T. (2021). Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study. J. Clin. Med.","DOI":"10.3390\/jcm10132758"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment","volume":"5","author":"Baumal","year":"2021","journal-title":"Ophthalmol. Retina"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","article-title":"Short-term outcomes of intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy","volume":"11","author":"Matsumoto","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.3389\/fphar.2021.720345","article-title":"Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice","volume":"12","author":"Montesel","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:50:50Z","timestamp":1760125850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["medicina59061110"],"URL":"https:\/\/doi.org\/10.3390\/medicina59061110","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}